Information between 14th April 2022 - 8th January 2025
Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.
| Arms Length Bodies Publications |
|---|
|
Nov. 13 2024
NICE Source Page: Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
Oct. 23 2024
NICE Source Page: Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
Oct. 23 2024
NICE Source Page: Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
Sep. 26 2024
NICE Source Page: Cabotegravir for preventing HIV-1 in adults and young people [ID6255] Publication Type: Draft guidance Document: Public committee slides PDF 882 KB (webpage) In consultation Found: and young people [ID6255] Part 1 Technology appraisal committee C [3rdSeptember 2024] Chair: Stephen O'Brien |
|
Sep. 26 2024
NICE Source Page: Cabotegravir for preventing HIV-1 in adults and young people [ID6255] Publication Type: Draft guidance Document: Draft guidance (downloadable version) PDF 295 KB (webpage) In consultation Found: Chair Stephen O'Brien Chair , technology appraisal committee C NICE project team Each evaluation |
|
Sep. 11 2024
NICE Source Page: Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
Sep. 11 2024
NICE Source Page: Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
Sep. 04 2024
NICE Source Page: Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
Aug. 14 2024
NICE Source Page: Linzagolix for treating moderate to severe symptoms of uterine fibroids Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
Aug. 08 2024
NICE Source Page: Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over Publication Type: Final draft guidance Document: Final draft guidance (PDF 316 KB) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committee C NICE project team Each evaluation |
|
Jul. 03 2024
NICE Source Page: Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair and vic e chair Stephen O'Brien and Richar d Nicholas Chair and vice chair , technology appraisal |
|
Jun. 19 2024
NICE Source Page: Tafamidis for treating transthyretin amyloidosis with cardiomyopathy Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
May. 28 2024
NICE Source Page: Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma Publication Type: Final draft guidance Document: Final draft guidance (PDF 168 KB) (webpage) Published Found: Chair and vice chair Stephen O'Brien and Richard Nicholas Chair and vice chair , technology appraisal |
|
May. 15 2024
NICE Source Page: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
May. 08 2024
NICE Source Page: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , Technology appraisal e valuation committ ee C. |
|
Mar. 20 2024
NICE Source Page: Momelotinib for treating myelofibrosis-related splenomegaly or symptoms Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
Mar. 13 2024
NICE Source Page: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair and vic e chair Stephen O'Brien and Richar d Nicholas Chair and vice chair , technology appraisal |
|
Jan. 31 2024
NICE Source Page: Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
Jan. 31 2024
NICE Source Page: Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
Sep. 06 2023
NICE Source Page: Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
Jun. 21 2023
NICE Source Page: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
Jun. 07 2023
NICE Source Page: Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Stephen O'Brien Chair , appraisal committ ee March 2023 Brexucabtagene aut oleucel f or treating r |
|
May. 31 2023
NICE Source Page: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committ ee C NICE pr oject team Each e valuation |
|
May. 18 2023
NICE Source Page: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction Publication Type: Final draft guidance Document: Final appraisal document (PDF 301 KB) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committee C CONFIDENTIAL UNTIL PUBLISHED Final |
|
May. 02 2023
NICE Source Page: Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma Publication Type: Final draft guidance Document: Public committee slides (PDF 1.23 MB) (webpage) Published Found: Second appraisal committee meeting Technology appraisal committee C [06thSeptember 2022] Chair: Stephen O'Brien |
|
May. 02 2023
NICE Source Page: Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma Publication Type: Final draft guidance Document: Final appraisal document (PDF 317 KB) (webpage) Published Found: Stephen O'Brien Chair, appraisal committee April 2023 4 Appraisal committee members and NICE project |
|
Mar. 29 2023
NICE Source Page: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , Technology appraisal e valuation committ ee C NICE pr oject team Each |
|
Feb. 08 2023
NICE Source Page: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction Publication Type: Draft guidance Document: Appraisal consultation document (PDF version) (PDF 304 KB) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committee C NICE project team Each evaluation |
|
Feb. 08 2023
NICE Source Page: Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction Publication Type: Draft guidance Document: Appraisal consultation document (PDF version) (PDF 292 KB) (webpage) Published Found: Chair Stephen O'Brien Chair , technology appraisal committee C NICE project team Each evaluation |
|
Dec. 14 2022
NICE Source Page: Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments Publication Type: Summary PDF Document: Download guidance (PDF) (webpage) Published Found: Chair Stephen O'Brien Chair , Technology appraisal e valuation committ ee C NICE pr oject team Each |
|
Oct. 19 2022
NICE Source Page: Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids Publication Type: Appeal Document: Appeal decision (MSWord 48 KB) (webpage) Published Found: the appraisal were present and available to answer questions from the appeal panel: Professor Stephen O'Brien |
|
Jul. 27 2022
NICE Source Page: Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma Publication Type: Draft guidance Document: Appraisal consultation document (PDF version) (PDF 285 KB) (webpage) Published Found: Stephen O'Brien Chair, appraisal committee July 2022 4 Appraisal committee members and NICE project |
|
Jul. 27 2022
NICE Source Page: Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma Publication Type: Draft guidance Document: Public committee slides (PDF 1.68 MB) (webpage) Published Found: low-grade non -Hodgkin lymphoma [ID1685] Technology appraisal committee C [05thJuly 2022] Chair: Stephen O'Brien |